Identifying markers to predict treatment response in pancreatic cancer patients

Prognostic and Predictive Markers of Treatment Response in Patients With Pancreatic Adenocarcinoma

This study is trying to find markers that can help doctors predict how well different treatments will work for people with pancreatic cancer.

Quick facts

• Study type: Observational
• Enrollment: 4050 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group (Academic / other)
• Drugs / interventions: chemotherapy
• Locations: 15 sites (Besançon and 14 other locations)
• Trial ID: NCT05776342 on ClinicalTrials.gov

What this trial studies

This observational study aims to identify prognostic and predictive markers that can help determine how patients with pancreatic adenocarcinoma respond to various treatments, including surgery and chemotherapy. By analyzing a multicenter cohort derived from current clinical practice, the study seeks to evaluate the effectiveness and tolerance of these treatments. The goal is to develop tools that can stratify patients based on their estimated survival, thereby guiding therapeutic decisions and optimizing patient selection for future clinical trials.

Who should consider this trial

Good fit: Ideal candidates for this study are adults aged 18 and older with histologically confirmed pancreatic adenocarcinoma at various stages of the disease.

Not a fit: Patients who are under guardianship, pregnant, breastfeeding, or unable to comply with the study protocol may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to more personalized treatment plans for pancreatic cancer patients, improving their outcomes.

How similar studies have performed: Other studies have shown promise in identifying prognostic markers in pancreatic cancer, suggesting that this approach could yield valuable insights.

Eligibility criteria

Inclusion Criteria:

* Patient with histologically confirmed pancreatic adenocarcinoma.
* Disease at a resectable, borderline, locally advanced, initially metastatic, or recurrent stage after surgery
* Diagnosis between January 1, 2003, and December 31, 2030.
* First-line treatment with chemotherapy and/or radiotherapy and/or clinical trials.
* Age ≥ 18 years.
* Written informed consent

Exclusion Criteria:

* Patient under guardianship, curatorship, or judicial protection.
* Pregnant or breastfeeding women.
* Any medical, psychological, or social situation that could prevent compliance with the protocol as assessed by the investigator.
* Refusal to participate in the study

Where this trial is running

Besançon and 14 other locations

• CHU Jean Minjoz — Besançon, France (Recruiting)
• Hôpital Beaujon — Clichy, France (Recruiting)
• CHU - Henri Mondor — Créteil, France (Not_yet_recruiting)
• CHU Lille — Lille, France (Recruiting)
• Centre Léon Bérard — Lyon, France (Not_yet_recruiting)
• HRU Nancy Site Brabois — Nancy, France (Recruiting)
• Hôpital Georges Pompidou — Paris, France (Recruiting)
• Hôpital Saint Antoine — Paris, France (Recruiting)
• Institut Mutualiste Montsouris — Paris, France (Not_yet_recruiting)
• CHU Poitiers — Poitiers, France (Not_yet_recruiting)
• CHU Reims — Reims, France (Not_yet_recruiting)
• CHU Pontchaillou — Rennes, France (Not_yet_recruiting)
• Institut Curie — Saint-Cloud, France (Not_yet_recruiting)
• IHU - Institut de chirurgie guidée par l'imagerie — Strasbourg, France (Not_yet_recruiting)
• Hôpital Paul Brousse — Villejuif, France (Recruiting)

Study contacts

• Principal investigator: Angelique VIENOT, MD — CHRU de Besançon - Institut Régional Fédératif du Cancer (IRFC) de Franche-Comté
• Study coordinator: Angelique VIENOT, MD

Conditions Pancreatic Adenocarcinoma